BAYRY Stock Recent News

Bayer said it was ordered to pay $2.1 billion in a case about its Roundup weedkiller after a jury in a Georgia state court reached a verdict in favor of the plaintiff.

Bayer was ordered by a jury in the U.S. state of Georgia to pay about $2.1 billion to a plaintiff who claimed the company's Roundup weed killer caused his cancer, the plaintiff's law firms said late on Friday.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Bayer's stock surged 24.5% since December 2024, yet remains a speculative investment due to significant risks like high debt and ongoing litigation. 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly; Pharmaceuticals saw slight growth, while Crop Science and Consumer Health declined. Bayer's 2025 outlook is uncertain, with potential sales growth of 1% at best; management remains optimistic about a turnaround by 2027.

The FDA accepts and grants priority review to BAYRY's sNDA for Kerendia to treat patients with a common form of heart failure.

Bayer said on Monday that it welcomed a new law about to be passed in the U.S. state of Georgia to better protect the maker of crop protection chemicals against glyphosate litigation.

Germany's Bayer has won an injunction to suspend a court ruling that gave Brazilian soybean farmers the right to reimbursement for royalties paid for expired patents of genetically modified soy seeds, according to a farmer group and a statement sent by the company to stakeholders this week.

Germany's financial markets watchdog has started an initial probe to examine whether Bayer fairly disclosed plans to get shareholder approval for a potential capital increase, a regulatory source told Reuters on Tuesday.

Bayer told several brokerages about plans to seek shareholder permission to issue shares one day before formally announcing the news on Friday, which weighed heavily on the stock, analysts' notes seen by Reuters showed.

Here is how Bayer Aktiengesellschaft (BAYRY) and AbbVie (ABBV) have performed compared to their sector so far this year.